Abstract
Recent developments in biopharmaceutical processes twined with a desire to remove cleaning and cross-contamination issues from drug production have led to the widespread introduction of single-use technologies and systems within operations. One key area that end users need to address with the advent of these single-use solutions is the potential for increased levels of extractables and leachables within a process, which need to be evaluated and understood as part of any regulatory submission. A science-based and practical method for characterization of extractables and leachables from single-use systems used in manufacturing antibody–drug conjugates has been developed and described in detail. This risk-based approach minimizes the amount of test work while meeting the regulatory requirements to ensure the drug safety and quality. The test design is optimized and the analytical methods (gas chromatography/mass spectrometry, liquid chromatography/mass spectrometry, and inductively coupled plasma/mass spectrometry) are shown to be suitable for quantifying and identifying the extracted chemical compounds. Application of this characterization method speeds up the filing process for qualification and validation of single-use systems used in bioprocesses.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Ritter A (2012) Antibody–drug conjugates. Pharma Technol 36(1):42–47
FDA (2006) Code of federal regulations food and drugs title 21, Part 211.65. US Government Printing Office, Washington, DC. http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfCFR/CFRSearch.cfm?fr=211.65&utm_campaign=Google2&utm_source=fdaSearch&utm_medium=website&utm_term=211.65&utm_content=1. Accessed 26 April 2012
EMA (1998) EUDRALEX Volume 4, Chap 3–Premise and Equipment, Section 3.39–Revised Directive 2003/94/EC: Good Manufacturing Practices, Medicinal Products for Human and Veterinary Use. European Commission: Brussels, Belgium. http://ec.europa.eu/health/files/eudralex/vol-4/pdfs-en/cap3_en.pdf. Accessed 26 April 2012
BPSA (2010) BPSA Extractables Guide 2010. Recommendations for testing and evaluation of extractables from single-use process equipment. http://www.bpsalliance.org/. Accessed 26 April 2012
Pall Life Sciences (2009) Validation guide. AllegroTM 2D Biocontainers. USTR 2475a.
Pall Life Sciences (2009) Validation guide. Kleenpak™ Connector for Use with 13 mm (12 inch) Nominal Tubing. USTR 2232a
Ding W, Nash R (2009) Extractables from integrated single-use systems in biopharmaceutical manufacturing Part I. Study on components (Pall KleenpakTM Connector and Kleenpak Filter Capsule). PDA J Pharm Sci Technol 63(4):322–338
Ding W, Martin J (2008) Implementing single-use technology in biopharmaceutical manufacturing: an approach to extractables/leachables studies, part one—connectors and filters. Bioprocess Int 6(9):34–42
Ding W, Martin J (2009) Implementation of single-use technology in biopharmaceutical manufacturing: an approach to extractables/leachables studies, Part two—tubing and biocontainers. Bioprocess Int 7(5):46–55
Ding W, Martin J (2010) Implementation of single-use technology in biopharmaceutical manufacturing an approach to extractables and leachables studies, Part three—single-use systems. Bioprocess Int 8(10):52–61
Pall Life Sciences (2012) Scientific and technical report. Extractables and Leachables from Single-Use Systems
ICH Q3C(R5) (2011) Impurities: guideline for residual solvents. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q3C/Step4/Q3C_R5_Step4.pdf. Accessed 26 April 2012
Product Quality Research Institute Leachables and Extractables Working Group (2006) Safety thresholds and best practices for extractables and leachables in orally inhaled and nasal drug products. http://www.pqri.org/pdfs/LE_Recommendations_to_FDA_09-29-06.pdf. Accessed 26 April 2012
Acknowledgment
The author appreciated the direction and guidance from Dr. Helene Pora, the constructive review from Bruce Rawlings, and the support from Sharon Klugewicz.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Ding, W. (2013). Risk-Based Scientific Approach for Determination of Extractables/Leachables from Biomanufacturing of Antibody–Drug Conjugates (ADCs). In: Ducry, L. (eds) Antibody-Drug Conjugates. Methods in Molecular Biology, vol 1045. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-62703-541-5_20
Download citation
DOI: https://doi.org/10.1007/978-1-62703-541-5_20
Published:
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-62703-540-8
Online ISBN: 978-1-62703-541-5
eBook Packages: Springer Protocols